Skip to main content

BIOXYTRAN INC

For the period ended Jun 30, 2024. Filed Aug 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 14, 2024

BIXTStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Date · # Shares · Amount · Price/Share · Type · Notice
1/17/2024(1)333,333$45,000$0.135private placement
1/18/2024(2)3,703,704500,0000.135debt conversion
1/18/2024(2)3,599,289485,9040.135debt conversionaffiliate
3/27/2024(2)3,705,808385,4040.104debt conversion
4/04/2024(2)1,000,000104,0000.104debt conversion
4/15/2024(1)173,07718,0000.104private placement
4/19/2024(2)250,00032,1250.129debt conversion
4/22/2024(1)194,55325,0000.128private placement
5/20/2024(2)1,027,397$150,000$0.146debt conversion
(1)The Company claims an exemption from the registration requirements of the Securities Act of 1933 (the “Securities Act”) for the private placement of these securities pursuant to Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated under the Securities Act.
(2)The Company claims an exemption from the registration requirements of the Securities Act pursuant to the Exchange Exemption in Rule 3(a)(9) of the Securities Act.

All funds received though these equity transactions has been used for general working capital expenses.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.